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Summary Heart failure is one of the most frequent reasons for hospitalization due to a cardiac
event. In most instances, the main difﬁculty is how to accurately evaluate left ventricular
ﬁlling pressure. It can be evaluated clinically, biologically and invasively. Although historically,
invasive management has been the reference, it is being used less and less frequently and
expertise in the technique is being lost. This paper discusses the strength and weaknesses of
the different techniques for evaluating ﬁlling pressure in these patients, and the importance
of this parameter for their optimal treatment.
© 2009 Elsevier Masson SAS. All rights reserved.
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Résumé L’insufﬁsance cardiaque est la cause la plus fréquente d’hospitalisation cardi-
ologique. La difﬁculté principale est généralement d’évaluer les pressions de remplissage
ventriculaires gauches. Elle peut être évaluée cliniquement, par prélèvement biologique ou
de fac¸on invasive. Bien qu’historiquement la prise en charge avec surveillance invasive ait été
la référence, le cathétérisme droit est de moins en moins utilisé et l’expertise qu’elle nécessiteFacteurs
natriuretiques
se raréﬁe. Cette revue discute les avantages et faiblesses des différentes techniques évaluant
les pressions de remplissage, ainsi que l’importance de ce paramètre pour le traitement optimal
des patients.
© 2009 Elsevier Masson SAS. Tous droits réservés.
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bbreviations
NP atrial natriuretic peptide
NP brain natriuretic peptide
F ejection fraction
V left ventricular
T-proBNP N-terminal prohormone brain natriuretic pep-
tide
roBNP prohormone brain natriuretic peptide
ackground
he management of acute heart failure is dependent largely
n clinical variables. The European Society of Cardiology
ask Force on Acute Heart Failure has deﬁned several
ifferent presentations (pulmonary oedema, cardiac decom-
ensation, cardiogenic shock and hypertensive crisis), which
ave also been used in the recent recommendations for both
cute and chronic heart failure, each of which has a speciﬁc
volution [1]. In the absence of easy standardization, there
s a growing interest in biomarkers and haemodynamic vari-
bles, which allow straightforward diagnostic classiﬁcation
nd may therefore guide therapy.
The use of biomarkers and echo-Doppler is a recent
evelopment, whereas pulmonary artery catheterization
as developed years ago, when acute myocardial infarction
as the main cause of acute heart failure. Pulmonary artery
atheterization allows us to obtain the LV ﬁlling pressure
hen alteration of ventricular function differs from one
ide of the ventricle to the other; right ventricular ﬁlling
ressure may be a misleading basis for estimation of LV
lling pressure.
hysiology of natriuretic peptides
atriuretic peptides have gained wide acceptance. ANP,
hich originates from the atrium, has a short half-life
around 3min), is less sensitive than BNP for the diagno-
is of heart failure and is no longer used in clinical practice.
NP, which is liberated from the ventricles, is almost absent
n healthy individuals but increases signiﬁcantly in patients
ith heart failure [2]. Both these natriuretic peptides are
egulated physiologically; when increased left atrial pres-
ure (for ANP) or diastolic LV wall stress (for BNP) is present,
heir secretion is increased and their plasma concentra-
ion rises. These peptides stimulate the generation of cyclic
uanosine monophosphate.
In reality, BNP is synthesized as pre-prohormone BNP,
hich is cleaved into prohormone BNP (proBNP). ProBNP
omprises the association of an N-terminal portion of
6 amino acids (NT-proBNP) with the active BNP molecule
f 32 amino acids (Fig. 1). Both fragments (NT-proBNP and
NP) are released into the blood and, in theory, are cleaved
efore release and can each be measured in the plasma.
owever, this last event appears to be altered in heart fail-
re, which means that assays may also measure the entire
roBNP molecule, which is released into the blood in these
atients [3,4]. The half-life of BNP is around 20min, whereas
hat of NT-proBNP is longer (60—120min). NT-proBNP is elim-
nated mainly by the kidney.
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atriuretic peptides for the diagnosis of
eart failure
atriuretic peptide biomarkers are used in the diagnosis of
cute heart failure; both BNP and NT-proBNP have been eval-
ated in patients admitted to an emergency department due
o dyspnoea, and both have shown high diagnostic value for
he conﬁrmation or ruling out of heart failure (Fig. 2).
The largest study on BNP was the Breathing Not Prop-
rly Study, published in 2002, which included 1586 patients
rriving at an emergency department with acute dyspnoea
5]; 47% appeared to have acute heart failure. Based on
his study, a cut-off value of 100 pg/ml was proposed, with
diagnostic accuracy of 83.4%. The area under the curve
f the receiver operating characteristic curve —a marker
f diagnostic value— was 0.91 (1.0 being perfect). This
iagnostic value was superior, and, more importantly, com-
lementary to that of the clinical evaluation [6]. However,
t may be wiser to consider this tool more as a contin-
um than as a black and white variable. Thus, a grey zone
ranging from 80—100 to 300—500 pg/mL) has been pro-
osed, with suggested conﬁrmation of heart failure above
00—500 pg/mL and suggested ruling out of heart failure
elow 80—100 pg/mL [1,7,8].
Similar ﬁndings have been obtained with NT-proBNP with
n initial cut-off value of 450 pg/mL for patients less than
0 years of age and 900 pg/mL for patients above or equal
o 50 years of age [9]. More recent studies favour ruling
ut heart failure when NT-proBNP is less than 300 pg/mL,
hereas the diagnosis of heart failure is considered to be
ikely when NT-proBNP is greater than 450 pg/mL in patients
ess than 50 years of age, greater than 900 pg/mL in patients
ged 50—75 years and greater than 1800 pg/mL in patients
bove 75 years of age [10]. The disadvantage of having dif-
erent cut-off values according to age for NT-BNP and BNP is
ompensated for by the fact that values are similar in differ-
nt centres, whereas the absolute value of BNP is dependent
n the type of assay. The values indicated earlier for BNP are
hose obtained using the triage method.
There has been a lot of discussion regarding possi-
le similarities in diagnostic accuracy between BNP and
T-BNP. Similar receiver operating characteristic curves
ere obtained in large independent multicentre studies
n patients coming to an emergency department for dysp-
oea (Fig. 2), and direct comparison of two assays in the
ame population indicated similar diagnostic values [11].
owever, due to the importance of renal elimination of NT-
roBNP, it has been suggested recently that a higher positive
ut-off value of 1200 pg/mL should be used in patients with
ltered renal function (i.e. glomerular ﬁltration rate less
han 60ml/min per 1.73m2) [12].
BNP will be used as a generic term for BNP and NT-proBNP
n the remainder of this paper.
actors other than heart failure that
ffect BNP plasma concentration
eart failure is not the only circumstance in which BNP
lasma concentration is increased [13]. An increase in right
entricular pressure triggers the release of BNP; pulmonary
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Figure 1. BNP cleavage from NT-proBNP. This mechanism appears to be altered in heart failure.
Figure 2. Diagnostic value of BNP (left) and NT-proBNP (right) in patients with acute dyspnoea seen in an emergency department. The
diagnostic values of BNP and NT-proBNP appear to be similar [5,9]. Diagnostic value of BNP (left) and NT-proBNP (right) in patients with
acute dyspnoea seen in an emergency department. The diagnostic values of BNP and NT-proBNP appear to be similar [5,9]. (Left: Receiver-
Operating-Characteristic curve for various cutoff levels of B-type natriuretic peptide [BNP] in differentiating between dyspnea due to
congestive heart failure and dyspnea due to other causes. Right: NT-proBNP was highly sensitive and speciﬁc for the diagnosis of acute CHF,
with a highly signiﬁcant area under the curve. A strategy of partitioning patients in age categories of < 50 and ≥ 50 years (with cutpoints of
450 and 900 pg/ml, respectively) was optimal, with areas under the curve of 0.98 and 0.93, respectively [p < 0.0001 for the two categories].
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mbolism and other aetiologies of pulmonary arterial hyper-
ension are therefore responsible for increased BNP plasma
oncentrations, which even carry a prognostic value in acute
ulmonary embolism [14—16]. BNP plasma concentration
lso increases in response to ischaemia and conveys prognos-
ic information during acute coronary syndrome [17]. Lastly,
NP plasma concentration appears to increase during sepsis,
ossibly as a result of LV systolic function depression [18].
Body mass index also alters BNP plasma concentra-
ions, which are lower in obese patients with heart failure
han in non-obese patients during acute decompensation
nd chronic patients (for heart failure of similar sever-
ty) [10,19]. It also appears that patients presenting very
arly after the acute onset of pulmonary oedema (‘‘ﬂash’’
ulmonary oedema) may have normal BNP plasma con-
entrations despite clear pulmonary oedema [7]; out of
4 patients arriving within 4 hours of pulmonary oedema
nset, four had BNP plasma concentrations less than
00 pg/mL, and 10 had BNP plasma concentrations greater
han 300 pg/mL, indicating that BNP plasma concentration is
ot a good indicator of acute heart failure decompensation
n this setting.
The measurement of BNP plasma concentration cannot
herefore be considered to be an absolute tool for the diag-
osis of heart failure in patients, but it complements the
nformation provided in clinical evaluation.
ractical use of BNP
hatever the limitations of BNP measurement for the diag-
osis of heart failure in the emergency department in
yspnoeic patients, its beneﬁt has been established ﬁrmly
y a randomized trial comparing the evolution of patients
rriving with dyspnoea who were managed either with the
nformation that heart failure was likely (if BNP > 500 pg/mL)
r unlikely (if BNP < 100 pg/mL), or with no additional infor-
ation (BNP between 100 and 500 pg/mL); the BNP plasma
oncentration was made available within 15min [8]. Com-
ared with the group of patients in whom BNP measurement
as not used, the time to treatment was shorter (63min
ersus 90min), the time to discharge was shorter (8 days
ersus 11 days) and the rates of hospital and intensive care
nit admissions were decreased (from 85 to 75% and from
4 to 15%, respectively). This beneﬁt was not negated by an
ncrease in mortality, either during hospitalization (6% ver-
us 9%) or after 30 days (10% versus 12%), nor by an increased
ate of readmission at 30 days.
V end diastolic pressure
stimation with BNP
ecause the stimulus for BNP secretion is LV end diastolic
tress rather than end diastolic pressure, a close correla-
ion between LV ﬁlling pressure (LV end diastolic pressure
r pulmonary artery occlusive pressure) and BNP plasma
oncentration is not expected (Fig. 3) [20]. In fact, many
tudies have conﬁrmed the loose relationship between these
wo values and, as a consequence, between the varia-
ion in LV ﬁlling pressure and the variation in BNP plasma
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oncentrations [21—23]. There is, nevertheless, a relation-
hip between the two values: BNP plasma concentration
ecreases in patients when pulmonary occlusive arterial
ressure decreases in response to treatment. This associ-
tion appears to be less obvious for NT-proBNP [24]. As a
esult, neither BNP nor NT-proBNP can be used to mon-
tor ﬁlling pressures in patients with heart failure. This
bservation, combined with the ‘‘grey zone’’ in which the
nformation given by the plasma concentration of BNP or
T-proBNP is moderate or null, has prompted a search for
lternative ways of estimating LV ﬁlling pressures. Doppler
chocardiography appears to be useful in this setting.
se of Doppler echocardiography
sing Doppler echocardiography of transmitral ﬂow, Logeart
t al. found a restrictive ﬁlling pattern very useful for reclas-
ifying patients who arrived very early (< 4 hours after onset
f pulmonary oedema) and patients in whom BNP plasma
oncentration was within the grey zone [7]. Restrictive pat-
ern was deﬁned as E/A above 2 or E/A between 1 and 2 and
deceleration time of E wave less than 130ms in patients in
inus rhythm, or simply a deceleration time of E wave less
han 130ms in those in atrial ﬁbrillation. This pattern was
resent in 11 of 14 patients arriving within 4 hours and seven
f 10 patients with acute heart failure with BNP plasma con-
entrations within the grey zone; the pattern was absent in
0 of 24 patients without heart failure with BNP plasma con-
entrations within the grey zone, including three in whom
oppler ﬂow could not be recorded.
Another echocardiographic variable that could be valu-
ble is the ratio of ﬂow Doppler mitral E wave peak velocity
nd early diastolic velocity of the mitral annulus obtained by
issue Doppler (a mean of the values obtained at the septum
nd the lateral wall) [25]. This ratio is related to pulmonary
apillary wedge pressure and its variation is also related
o the variation in capillary wedge pressure, although the
orrelation is not strong enough to allow the use of one vari-
ble instead of the other; nevertheless, it enables patients
ith elevated pulmonary capillary wedge pressure (deﬁned
s > 15 mmHg) to be identiﬁed accurately. A cut-off value
f 15 has been proposed for all patients, although whether
atients with systolic dysfunction should be distinguished
rom patients with preserved EF is under discussion. The
ptimal value remained at 15 in patients with systolic dys-
unction (EF < 50%), but a value of 11 was proposed in
atients with preserved LV systolic function (EF > 50%) [22].
hese data were obtained in patients with diverse patholo-
ies, but similar values were obtained in patients with heart
ailure alone (11 for patients with an EF greater than 45%
nd 14 in patients with an EF less than 45%) [26]. Therefore,
n clinical practice, Doppler mitral ﬂow appears to be useful
n association with BNP when the diagnosis remains dubi-
us, but monitoring of instantaneous ﬁlling pressures with
iomarkers appears to be ineffective.rognosis of heart failure patients
onitoring may have other purposes, such as stratiﬁcation of
atient prognosis. The prognostic value of BNP or NT-proBNP
lasma concentrations has been established in a wide-range
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tFigure 3. Relationship between BNP plasma concentration and
stress (SWS lower left) and end-diastolic wall stress (EDWS, lower ri
wall stress and not end-diastolic pressure or indices of LV systolic fu
of conditions; in patients with chronic heart failure, a high
‘‘baseline’’ BNP plasma concentration is associated with
an increased risk of death [27]. The absolute value of BNP
also carries prognostic information during and after decom-
pensation, and its variation during hospitalization is also
meaningful.
Cheng et al. reported that BNP plasma concentra-
tions increased during hospitalization in patients who died,
whereas they decreased in patients who were not rehospi-
talized or did not die [28]. In those readmitted, BNP plasma
concentrations remained stable. The most valuable prog-
nostic information appears to come from the BNP plasma
concentration at discharge after treatment optimization
[29]. This is also true for the pulmonary capillary pressure;
its prognostic value is greater after optimization of medical
therapy [30].Other biomarkers have been shown to have prognostic
value in patients with heart failure, either during decompen-
sation or when in a stable condition. Troponin, C-reactive
protein and interleukin-6, or more simple indexes such as
creatinine or natremia, can also be used for this purpose.
w
o
m
c
ipper left), end-diastolic pressure (EDP upper right), systolic wall
This last correlation is the strongest, suggesting that end-diastolic
n can be evaluated with BNP plasma concentration [20].
daptation of heart failure therapy
ecause of its prognostic value, the use of BNP plasma
oncentration to monitor therapy in patients with chronic
eart failure has been proposed. As this is not the topic
f this review, we have discussed the two existing studies
rieﬂy. The ﬁrst study involved 69 patients with heart fail-
re, very few of whom received beta-blockers [31]. A target
T-proBNP plasma concentration of less than 200 pg/mL was
ssociated with a 65% decrease of hospitalization or death
uring a mean follow-up of 9months compared with clinical
ollow-up alone. The Systolic Heart Failure Treatment Sup-
orted by BNP (STARS-BNP) study included 220 patients and
andomized patients to be followed up clinically or with BNP
lasma concentration measurement, with a target concen-
ration of less than 100 pg/mL [32]. This BNP-guided therapy
as associated with a decrease in hospitalization or death
f 50% (Fig. 4). Patients with BNP plasma concentration
easurements received higher doses of all medication, indi-
ating that the availability of a BNP plasma concentration
s a motivating force in increasing the use of recommended
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Figure 4. Rate of survival without hospitalization in the STARS-
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Figure 5. Clinical evolution of patients who did or did not receive
a pulmonary artery catheter in the ESCAPE trial (left). No subgroup
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mNP study in the group followed up in terms of clinical variables
clinical group, closed circles) and in the group followed up in terms
f BNP plasma concentration (BNP group, open circles) [32].
herapy. In reality, only 30% of the patients actually reached
BNP plasma concentration less than 100 pg/mL.
Very recently, a multicenter study reported that moni-
oring of Nt-BNP in patients with LVEF less than 45% did not
hange survival free of all-cause hospitalization in the whole
opulation. However, in the subgroup of patients younger
han 75 years, and in the subgroup of patients without more
han one comorbidity, interaction suggested beneﬁt on sur-
ival, hospital-free survival and heart failure hospital free
urvival. In this study, the aim was to decrease Nt-BNP to
ess than 400 pg/mL if above 75 years of age and less than
00 pg/ml if above 75 years of age [33].
nterpreting LV ﬁlling pressure, right heart
atheterization
he cardiologist’s Holy Grail is to establish LV ﬁlling pressure.
owever, this variable is difﬁcult to interpret for several
easons. Firstly, the estimation of LV ﬁlling pressure using a
ulmonary artery catheter is subject to error, as it can only
easure the pulmonary capillary wedge pressure, which is
ot always a good indication of end diastolic LV pressure.
he difference between the two values increases as the
tiffness of the left ventricle increases, i.e. as left atrial
ontraction contribution increases in the LV ﬁlling. Secondly,
he optimal value for LV ﬁlling pressure may be difﬁcult to
eﬁne; in a stable patient with chronic LV systolic dysfunc-
ion, a baseline pulmonary wedge pressure of 15mmHg or
ven 20mmHg may be seen. Because lymphatic removal of
xuding ﬂuid may be greatly enhanced in this population,
hese high values may not be associated with pulmonary
edema, and trying to decrease this pressure acutely to a
‘normal’’ level would be a mistake. At the other extreme,
n acute pulmonary oedema occurring in a patient with LV
iastolic dysfunction but without chronic heart failure may
ccur with a much lower pulmonary capillary wedge pres-
ure value. However, decreasing the LV pressure may lead to
nderﬁling of the left ventricle and acute decrease of car-
iac output. Thus, the interpretation of the absolute value
f pulmonary artery capillary pressure obtained during acute
p
f
c
i
tppeared to beneﬁt from the pulmonary artery catheter in this study
right) [34].
aemodynamic distress and the choice of an optimal value
or the patient are not obvious.
If LV ﬁlling pressure were the most important variable, its
ontinuous measurement using a pulmonary artery catheter
hould facilitate optimal medical therapy. However, the
eneﬁt of pulmonary artery catheterization in the manage-
ent of patients with acute heart failure has not yet been
stablished. All the randomized studies, comparing care
f patients with and without pulmonary artery catheteri-
ation, have been negative, reporting no beneﬁt and only
dverse effects (Fig. 5). These results were obtained in dif-
erent populations, which were either heterogeneous (with
hock or acute respiratory distress syndrome or both) and
anaged in intensive care units, usually by non-cardiologist
hysicians or more homogeneous, with pronounced heart
ailure and managed by cardiologists [34—36]. It is cru-
ial that the physician is familiar with the technique, if
t is to be used properly and with optimal beneﬁt. Fur-
hermore, full beneﬁt cannot be expected to be obtained
press
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when only occasional measurements are made, as the main
advantage of this technique is the availability of repeated
measures of haemodynamic variables. The use of a pul-
monary artery catheter remains useful in expert hands to
manage haemodynamically unstable patients who are not
responding in a predictable fashion to traditional treat-
ments, and in patients with a combination of congestion and
hypoperfusion. In these cases, it is inserted to ensure opti-
mal ﬂuid loading of the ventricles and to guide vasoactive
therapies and inotropic agents [37].
Repeated disappointment and technical difﬁculties,
availability of alternative techniques and the progress made
with echocardiography (including tissue Doppler imaging)
are responsible for a decrease in the use of the pulmonary
artery catheter. Besides, and probably most importantly,
the importance given to haemodynamic optimization dur-
ing acute heart failure decompensation is decreasing [38],
because of the repeated observation during randomized tri-
als in acute heart failure that haemodynamic improvement
does not result in decreased duration of hospitalization or
decreased mortality. This questioning of the value of haemo-
dynamic variables during the acute phase of heart failure
is reﬂected in the fact that even the regulatory agencies
are shifting the endpoints from haemodynamic variables to
functional ones (e.g. dyspnoea and well-being) and clinically
relevant data (hospitalization duration and mortality) [39].
In fact, numerous variables are readily available in
patients with heart failure during the acute phase of
decompensation. Afterload can be established using arterial
pressure, cardiac output can be evaluated with clinical vari-
ables and echocardiography (Doppler study of aortic ﬂow),
and right ventricular ﬁlling pressure can be gauged via clin-
ical signs of right-sided congestion or the study of inferior
vena cava on echocardiography. Only LV ﬁlling pressure is
difﬁcult to evaluate directly, and may differ from right ven-
tricular ﬁlling pressure if a cardiopathy is localized to the
left side, such as in acute myocardial infarction or LV hyper-
trophy in response to hypertension.
In conclusion, monitoring patients during acute decom-
pensation is usually done on clinical grounds. Biomarkers
may be of help for diagnostic purposes and determin-
ing patient prognosis, the most valuable information being
probably derived after treatment optimization. Echocardio-
graphy Doppler and tissue Doppler are complementary tools.
Haemodynamic monitoring is today seldom necessary in
patients with acute heart failure. However, tomorrow, con-
tinuous haemodynamic monitoring through implanted leads
may be available, and, if proved to be useful, may lead to
reconsider our rules [40].
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